Alder BioPharmaceuticals® announces first-in-human dosing in phase 1 ALD1910 study
Alder announced dosing of the first patient in a Phase 1 clinical study to evaluate ALD1910 as a preventive treatment for migraine. ALD1910 is an investigational monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide, an important signaling molecule of migraine. October 10, 2019